This conference is closed.
Stimulant Safety in ADHD Virtual Seminar
Wednesday, September 3, 2025
1:00 p.m. to 3:00 p.m. EDT
The Diversion Control Division of the Drug Enforcement Administration is pleased to present a seminar about Stimulant Safety in ADHD.
There is no registration fee for this event. Capacity is limited to the first 3,000 attendees.
ADHD is the most common neurobehavioral disorder presenting for treatment. The stimulants including methylphenidate and amphetamine are among first line treatments, but the stimulants have abuse liability and the nonmedical use (NMU) including misuse and diversion has been of great interest to practitioners.
Data on the use of stimulants in ADHD, and the diversion and misuse of stimulants in those with and without a diagnosis of ADHD, will be examined during this seminar.
Speakers include:
- Timothy E. Wilens, MD, Chief of Child and Adolescent Psychiatry, Massachusetts General Hospital; Professor, Harvard Medical School
- Sean McCabe, PhD, Director of Center for the Study of Drugs, Alcohol, Smoking and Health (DASH Center); Professor, University of Michigan
- Matthew Strait, DEA Deputy Assistant Administrator
- Amy Yule, MD, Vice Chair, Addiction Psychiatry, Boston Medical Center; Associate Professor, Boston University
Secondary registration is required. Upon the completion of the secondary registration, participants will receive a ZOOM link to access the Webinar. Participants should use the same email address for the secondary registration as they did for the primary registration.
This conference is closed.
Any questions regarding this conference may be directed to: VDAT@dea.gov